Back

Association of Inappropriate Dosing of Non-Vitamin K Oral Anticoagulants and Risk of Adverse Events: Results from the ORBIT-AF II Registry

29 August 2016 (09:30 - 09:45)
Organised by:
Congress Presentation Part of: Registries atrial fibrillation Atrial fibrillation (AF) ESC Premium Access ESC Congress 2016

About the speaker

Photo
Professor Jonathan Piccini

Duke University Medical Center, Durham (United States of America)

5 More presentations in this session

Presentation thumbnail
Identifying patients with atrial fibrillation and "truly low" thromboembolic risk who are poorly characterized by CHA2DS2-VASc: Superior performance of a novel machine learning tool in GARFIELD-AF
Professor K. Fox (Edinburgh, GB)
Slides Video
Presentation thumbnail
A nationwide register study to compare bleeding rates in patients with non-valvular atrial fibrillation prescribed oral anticoagulants
Professor S. Halvorsen (Oslo, NO)
Slides Video
Presentation thumbnail
ESC-EURObservational Research Programme: In-hospital and 1-year follow-up of the Long-term Atrial Fibrillation Ablation Registry, Conducted by the European Heart Rhythm Association
Associate Professor E. Arbelo (Barcelona, ES)
Slides Video
Presentation thumbnail
XAPASS: Evidence of Safety and Effectiveness in Japanese Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation under Real-World Clinical Practice
Professor T. Ikeda (Tokyo, JP)
Slides Video
Presentation thumbnail
A Large-Scale Multi-Center Registry of Patients Undergoing Radiofrequency Catheter Ablation for Atrial Fibrillation: Kansai Plus Atrial Fibrillation Study
Doctor S. Shizuta (Wakayama, JP)
Slides Video

Access the full session

Session thumbnail
Registries atrial fibrillation

The Event

Event poster

ESC Congress 2016

29 August 2016 09:30 CET
You may be interested in
thumbnail
Congress Presentation
1 September 2019
thumbnail
Congress Presentation
One year after the 2021 EHRA practical guide on NOACs: main points and new aspects.
3 April 2022
thumbnail
Congress Presentation
Safety and effectiveness of edoxaban in a real-world clinical setting: Two-year follow-up of the ETNA-AF-Europe study
25 April 2021
thumbnail
Congress Presentation
31 August 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources